

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application.

**LISTING OF CLAIMS**

1. **(currently amended)** A [[M]]micronutrient combination product characterized in that the micronutrient combination product comprises comprising: 0.1-2 mg of zeaxanthin, 2-40 mg of lutein, 2-80 mg of zinc, and 0.02-2 mg of copper, wherein the micronutrient combination product is free of beta-carotene, and comprises a daily dosage administrable to a subject.
2. **(canceled)**
3. **(currently amended)** The [[M]]micronutrient combination product according to claim 1, characterized in that the micronutrient combination product contains further comprising at least one vitamin[.] selected from the group consisting of preferably vitamin C, and/or vitamin E, and combinations thereof.
4. **(currently amended)** The [[M]]micronutrient combination product according to claim [[1]] 3, characterized in that the micronutrient combination product comprises the following agents, as related to one daily dose of the micronutrient combination product:
  - a. 2 mg to 40 mg, preferably 6 mg to 24 mg, lutein;
  - b. 0.1 mg to 2 mg, preferably 0.3 mg to 1.2 mg, zeaxanthin;
  - c. 50 mg to 500 mg, preferably 75 mg to 300 mg, vitamin C;
  - d. 2 mg to 60 mg, preferably 7.5 mg to 30 mg, vitamin E;
  - e. 0.02 mg to 2 mg, preferably 0.2 mg to 0.08 mg, copper;

f. 1 mg to 80 mg, preferably 10 mg to 40 mg, zinc, wherein said vitamin C is in an amount of 50-500 mg, and said vitamin E is in an amount of 2-60 mg.

5. (currently amended) The [[M]]micronutrient combination product according to claim 1, characterized in that wherein the micronutrient combination product is available as a solid, a liquid, and/or or a gel; preferably, the micronutrient combination product is available in forms of preparation selected from the group comprising tablets, film-coated tablets, sugar-coated pills, capsules, powders, granulate, solutions, and/or effervescent tablets.
6. (currently amended) The [[M]]micronutrient combination product according to claim 1, characterized in that wherein the micronutrient combination product is available in a solid dosage form, wherein the having a core of the dosage form constitutes from 200 mg to 1000 mg; preferably 400 mg to 800 mg, and preferably 600 mg.
7. (currently amended) The [[M]]micronutrient combination product according to claim 1, characterized in that the micronutrient combination product contains further comprising an adjuvant[[s]] selected from the group comprising consisting of lactose, povidone, cellulose, and/or cellulose derivatives, microcrystalline cellulose, starch, and/or starch derivatives, magnesium stearate, stearic acid, gelatin, sodium aluminum silicate, silica, maltodextrin, dextrose, talcum, titanium dioxide, calcium carbonate, vegetable fats, tricalcium phosphate, antioxidants, stabilizers, Arabic gum, calcium phosphates, calcium silicate, sucrose, sodium citrate, citric acid, and and/or gustatory corrigents.
8. (currently amended) The [[M]]micronutrient combination product according to claim 1, characterized in that the micronutrient combination product contains further comprising a coating substance[[s]] selected from the group comprising cellulose, and/or cellulose derivatives, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and/or microcrystalline cellulose, titanium dioxide, dyes, talcum, polymethacrylates, shellac, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycols, triacetin, triethyl citrate, propylene glycol, glycerol, Arabic gum, silica, glycerol monostearate, and and/or cotton seed oil.
9. (currently amended) The [[M]]micronutrient combination product according to claim [[1]] 7, characterized in that the micronutrient combination product contains zeaxanthin, lutein, wherein said zinc comprises zinc gluconate, said copper comprises copper (II)

gluconate, said vitamin E comprises vitamin E acetate, said vitamin C comprises ascorbic acid, and said adjuvant comprises cellulose, lactose, and/or or magnesium stearate.

10. **(currently amended)** The [[M]]micronutrient combination product according to claim 1, characterized in that wherein the micronutrient combination product comprises the following agents, as related to is one daily dose of the micronutrient combination product consisting of:

- a. 12 mg lutein;
- b. 0.6 mg zeaxanthin;
- c. 150 mg vitamin C;
- d. 15 mg vitamin E;
- e. 0.4 mg copper;
- f. 20 mg zinc; and
- g. an adjuvant.

11. **(currently amended)** The [[M]]micronutrient combination product according to claim 1, characterized in that wherein the micronutrient combination product comprises the following agents, as related to is one single daily dose consisting of the micronutrient combination product two units, each unit consisting of:

- a. 6 mg lutein;
- b. 0.3 mg zeaxanthin;
- c. 75 mg vitamin C;
- d. 7.5 mg vitamin E;
- e. 0.2 mg copper;

f. 10 mg zinc; and

g. an adjuvant.

12. (currently amended) A process Use of for manufacturing a micronutrient combination product, the process comprising: (a) preparing a mixture comprising zeaxanthin, lutein, zinc, copper, and an adjuvant; and (b) forming the mixture into a daily dosage unit, wherein said mixture is free of beta-carotene, and wherein said zeaxanthin in said daily dosage unit is present in an amount of 0.1-2 mg, said lutein in said daily dosage unit is present in an amount of 2-40 mg, said zinc in said daily dosage unit is present in an amount of 2-80 mg, and said copper in said daily dosage unit is present in an amount of 0.02-2 mg according to claim 1 for manufacturing a means for dietetic prevention and/or treatment of diseases of the eye, preferably in cases of age-related macular degeneration.

13. (currently amended) A method of supplementing Use of a micronutrient combination product according to claim 1 as a means for a supplementary balanced diet of a subject, said method comprising administering to said subject a micronutrient combination product of claim 1.

14. (currently amended) Means for a supplementary balanced diet, in particular food, comprising agents according to claim 1 The method of claim 13, wherein said subject is at risk of developing age-related macular degeneration.